{"id":"arthemether-lumefantrine","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Headache"},{"rate":"5-15","effect":"Fever"},{"rate":"5-10","effect":"Nausea"},{"rate":"3-8","effect":"Vomiting"},{"rate":"3-8","effect":"Diarrhea"},{"rate":"5-10","effect":"Abdominal pain"},{"rate":"3-7","effect":"Dizziness"},{"rate":"1-3","effect":"Palpitations"},{"rate":"1-2","effect":"QT prolongation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Artemether, a semi-synthetic artemisinin derivative, rapidly kills malaria parasites by generating reactive oxygen species that damage parasite proteins and DNA. Lumefantrine, an arylaminoalcohol, inhibits the parasite's ability to detoxify heme released during hemoglobin digestion, leading to parasite death. Together, they provide rapid parasite clearance and sustained suppression of parasitemia.","oneSentence":"Artemether and lumefantrine work synergistically to kill malaria parasites by disrupting their hemoglobin metabolism and interfering with their DNA replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:42:43.888Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Uncomplicated malaria caused by Plasmodium falciparum"},{"name":"Malaria caused by Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae"}]},"trialDetails":[{"nctId":"NCT00422084","phase":"PHASE3","title":"Pyronaridine Artesunate (3:1) Versus Coartem® in P Falciparum Malaria Patients","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2007-01","conditions":"Malaria","enrollment":1272},{"nctId":"NCT02001012","phase":"PHASE3","title":"P. Knowlesi Trial of Artemether-lumefantrine vs Chloroquine","status":"COMPLETED","sponsor":"Menzies School of Health Research","startDate":"2014-01","conditions":"Uncomplicated Knowlesi Malaria","enrollment":123},{"nctId":"NCT01084213","phase":"PHASE4","title":"Intermittent Preventive Treatment Versus Scheduled Screening and Treatment of Malaria in Pregnancy","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2010-06","conditions":"Malaria, Pregnancy, Anaemia","enrollment":5354},{"nctId":"NCT00540410","phase":"PHASE4","title":"Cohort Study in Senegal Comparing Artesunate + Amiodaquine in the Treatment of Repeated Uncomplicated Plasmodium Falciparum Malaria Attacks","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-09","conditions":"Malaria","enrollment":366},{"nctId":"NCT00452907","phase":"PHASE4","title":"ACT MALI: Treatment of Malaria Based on Combination Therapies","status":"COMPLETED","sponsor":"Sanofi","startDate":"2005-07","conditions":"Malaria","enrollment":780}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"arthemether + lumefantrine","genericName":"arthemether + lumefantrine","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Artemether and lumefantrine work synergistically to kill malaria parasites by disrupting their hemoglobin metabolism and interfering with their DNA replication. Used for Uncomplicated malaria caused by Plasmodium falciparum, Malaria caused by Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}